Rhumbline Advisers Prometheus Biosciences, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$103.46 - $126.29 $316,173 - $385,942	3,056 Added 6.93%	47,127 $5.06 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $217,622 - $707,362	6,035 Added 15.87%	44,071 $4.85 Million
Q3 2022 Nov 10, 2022	BUY	$28.17 - $59.01 $132,483 - $277,524	4,703 Added 14.11%	38,036 $2.25 Million
Q2 2022 Aug 11, 2022	SELL	$22.39 - $38.94 $86,067 - $149,685	-3,844 Reduced 10.34%	33,333 $941,000
Q1 2022 May 12, 2022	BUY	$30.13 - $50.0 $36,939 - $61,300	1,226 Added 3.41%	37,177 $1.4 Million
Q4 2021 Feb 10, 2022	BUY	$22.28 - $39.54 $558,269 - $990,753	25,057 Added 230.01%	35,951 $1.42 Million
Q3 2021 Nov 12, 2021	BUY	$20.89 - $26.96 $10,967 - $14,154	525 Added 5.06%	10,894 $258,000
Q2 2021 Aug 05, 2021	BUY	$16.8 - $29.65 $174,199 - $307,440	10,369 New	10,369 $255,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.